Drug survival of biologic treatments in psoriasis: a systematic review.

about

The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review.Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence

P2860

Q54214331-5B61E778-2332-4FE1-B5D8-5100E7250AC4 Q58099097-6DB2BBAF-9AF2-4531-BEB5-72BF63560C4A

P2860

Drug survival of biologic treatments in psoriasis: a systematic review.

Item

http://www.wikidata.org/entity/Q46118586

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Drug survival of biologic treatments in psoriasis: a systematic review.

@en

Drug survival of biologic treatments in psoriasis: a systematic review.

@nl

type

Item

label

Drug survival of biologic treatments in psoriasis: a systematic review.

@en

Drug survival of biologic treatments in psoriasis: a systematic review.

@nl

prefLabel

Drug survival of biologic treatments in psoriasis: a systematic review.

@en

Drug survival of biologic treatments in psoriasis: a systematic review.

@nl

P1476

Drug survival of biologic treatments in psoriasis: a systematic review

@en

P2093

Daniel J No

http://www.w3.org/2001/XMLSchema#string

Megan S Inkeles

http://www.w3.org/2001/XMLSchema#string

Mina Amin

http://www.w3.org/2001/XMLSchema#string

P2860

Immunogenicity of biotherapy used in psoriasis: the science behind the scenes

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Safety of treatment with biologics for psoriasis in daily practice: 5-year data.

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis.

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

P304

460-466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09546634.2017.1398393

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jashin J. Wu

P577

2017-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29076754

http://www.w3.org/2001/XMLSchema#string

Drug survival of biologic treatments in psoriasis: a systematic review.

about

P2860

P2860

Drug survival of biologic treatments in psoriasis: a systematic review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698